"Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis"
In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) & Region- Global Forecast to 2030

The global in vitro diagnostics (IVD) market is entering a phase of accelerated expansion, with industry valuation climbing from $101.05 billion in 2024 to $109.06 billion in 2025 and forecast to reach $157.63 billion by 2030—representing a compound annual growth rate (CAGR) of 7.6% during the 2025-2030 period.

What is driving this growth trajectory? Market momentum is anchored in the escalating prevalence of chronic and infectious diseases worldwide, the intensifying demand for rapid and precise diagnostic capabilities, and the strategic shift toward personalized medicine across healthcare systems. These forces are reshaping diagnostic workflows, investment priorities, and competitive dynamics across laboratories, hospitals, and point-of-care environments.

Strategic Market Insights: Where Value and Innovation Converge

Why does this matter for C-suite decision-makers? The IVD market represents a critical infrastructure layer supporting clinical outcomes, operational efficiency, and population health management. Strategic positioning within this market requires understanding where growth, technology, and end-user demand intersect.

North America maintains commanding market leadership, accounting for 38.7% of global IVD revenue in 2024, supported by advanced healthcare infrastructure, robust regulatory frameworks, and widespread adoption of molecular and immunoassay platforms. This regional dominance reflects sustained investment in precision diagnostics and digital health integration.

Reagents and kits constitute the market's revenue backbone, capturing 69.0% of global share in 2024. This segment's leadership stems from recurring consumable demand, high testing volumes, and essential deployment across all diagnostic platforms—from molecular workflows to clinical chemistry and immunoassays.

Who is positioned to capitalize on fastest-growing segments? Molecular diagnostics technology is projected to register the highest CAGR of 14.5% from 2025 to 2030, driven by advances in PCR, next-generation sequencing, and multiplexing capabilities. Point-of-care testing represents the fastest-growing site-of-testing segment, fueled by decentralization trends and demand for near-patient diagnostic solutions.

Technology Disruption and Clinical Transformation

How are technological advances reshaping the market? Innovations in chemiluminescence assays, digital diagnostic platforms, and automated high-throughput analyzers are enhancing clinical efficiency and accelerating decision-making timelines. The integration of artificial intelligence, data analytics, and connectivity into diagnostic systems is fundamentally transforming laboratory operations and test result interpretation.

Blood, serum, and plasma specimens continue to dominate specimen types due to broad clinical applicability and compatibility with diverse diagnostic modalities. Infectious disease applications accounted for the largest application share in 2024, reflecting persistent global demand for pathogen screening, outbreak response, and chronic infection monitoring.

Hospitals and clinics remain the largest end-user segment, driven by high patient volumes, comprehensive testing requirements, and integration of advanced molecular platforms and immunoassay analyzers within clinical workflows.

Competitive Landscape: Market Leaders and Emerging Innovators

Who are the dominant players shaping market evolution? F. Hoffmann-La Roche, Danaher, and Abbott have been identified as Star players within the global IVD competitive matrix, distinguished by extensive diagnostic portfolios, substantial market presence, and sustained leadership across high-value testing segments including molecular diagnostics, immunoassays, and clinical chemistry.

Among small and medium enterprises, Devyser and Surmodics have carved out strong positions in specialized diagnostic niches, demonstrating innovation potential and strategic agility within targeted market segments.

Market Dynamics: Navigating Opportunities and Challenges

What opportunities are emerging for strategic investors? Improvements in immunoassay diagnostic technologies—including high-sensitivity platforms, automation capabilities, and multiplexing functions—are creating substantial growth avenues. Developing markets present significant expansion opportunities as healthcare infrastructure modernizes and early disease detection awareness increases.

When do regulatory and operational barriers pose constraints? Stringent regulatory requirements, particularly IVDR compliance in Europe and FDA standards in the United States, extend product development timelines and increase compliance costs. Operational challenges including skilled labor shortages, instrument maintenance expenses, and supply chain vulnerabilities continue to affect deployment efficiency and testing consistency.

Data privacy and cybersecurity risks represent emerging challenges as diagnostic systems become increasingly connected and data-intensive.

Industry Use Cases: Validated Commercial Applications

Leading diagnostic platforms demonstrate measurable performance advantages across clinical settings. Roche's cobas molecular systems deliver high-throughput viral load testing with superior analytical accuracy and automated workflows for centralized laboratories. Abbott's Alinity m analyzers provide rapid molecular detection with minimal manual intervention for infectious disease diagnostics. Cepheid's GeneXpert systems enable decentralized, cartridge-based molecular testing suitable for point-of-care and low-resource environments.

Siemens Healthineers' Atellica CI Analyzer integrates clinical chemistry and immunoassay testing to improve operational efficiency and turnaround times in hospital laboratories. Illumina's NextSeq 550Dx instrument supports high-throughput next-generation sequencing for oncology and genetic testing applications, advancing precision medicine capabilities.

Market Ecosystem and Value Chain Integration

Where does collaboration drive market advancement? The IVD ecosystem comprises specialized suppliers including Abacus ALS, diagnostic manufacturers, and major healthcare institutions such as Cleveland Clinic, Johns Hopkins Medicine, and Unilabs. Suppliers provide critical reagents, consumables, and instrument components. Healthcare institutions drive demand for accuracy, speed, and high-throughput capabilities to support clinical decision-making and population health initiatives.

Sustained collaboration across suppliers, manufacturers, and diagnostic service providers remains essential to ensure innovation velocity, regulatory compliance, and improved clinical outcomes.

Regional Market Dynamics

North America's market leadership through 2030 is reinforced by advanced healthcare infrastructure, high adoption rates of molecular and immunoassay technologies, and substantial investments in precision medicine and digital diagnostic platforms. Growing demand for infectious disease testing, chronic disease monitoring, and rapid diagnostic workflows further solidifies the region's dominant position.

Recent Strategic Developments

February 2025: F. Hoffmann-La Roche Ltd introduced a novel class of next-generation sequencing powered by proprietary Sequencing by Expansion (SBX) technology, targeting enhanced accuracy, efficiency, and scalability.

November 2024: F. Hoffmann-La Roche Ltd entered a definitive merger agreement to acquire Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in donor-derived CAR-T cell therapies, strengthening its cell and gene therapy portfolio.

July 2024: Beckman Coulter, Inc. and Fujirebio announced collaboration to identify novel blood-based biomarkers and advance existing biomarker development for tau pathology in Alzheimer's disease.

Strategic Implications for Decision-Makers

The in vitro diagnostics market represents a convergence of clinical necessity, technological innovation, and commercial opportunity. Organizations positioned to capitalize on molecular diagnostics growth, point-of-care testing expansion, and immunoassay technology improvements will secure competitive advantages in an increasingly precision-driven healthcare landscape.

Strategic investment priorities should emphasize automation capabilities, regulatory compliance infrastructure, data security frameworks, and partnership ecosystems that accelerate market access and clinical validation.

Market Scope and Methodology

This analysis encompasses comprehensive evaluation across product categories (reagents & kits, instruments, data management software), technology platforms (immunoassays, clinical chemistry, molecular diagnostics, glucose monitoring, hematology, microbiology, coagulation, blood gas analyzers, urinalysis, chromatography), specimen types, testing sites, clinical applications, and end-user segments across North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and GCC countries.

The forecast period extends from 2025 to 2030, with 2024 as the base year. Market sizing includes value metrics (USD million/billion) and volume considerations, supported by secondary research, expert interviews, and comprehensive competitive analysis.

Key Market Participants

Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Thermo Fisher Scientific, Inc. (US), Illumina, Inc. (US), Hologic, Inc. (US), Bio-Rad Laboratories, Inc. (US), bioMérieux (France), Sysmex Corporation (Japan), Revvity Inc (US), Becton, Dickinson and Company (US), Agilent Technologies, Inc. (US), Qiagen (Netherlands), DiaSorin S.p.A. (Italy), Grifols, S.A. (Spain), Werfen (Spain), QuidelOrtho Corporation (US).

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html

 

Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: In Vitro Diagnostics Market Size to Worth $157.63 Billion by 2030

Information contained on this page is provided by an independent third-party content provider. XPRMedia and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact [email protected]